LeMaitre Vascular (NASDAQ:LMAT) Sets New 52-Week High at $91.78

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $91.78 and last traded at $91.67, with a volume of 152132 shares traded. The stock had previously closed at $86.17.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Lake Street Capital began coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Monday, August 12th. Roth Mkm reaffirmed a “buy” rating and issued a $100.00 price target on shares of LeMaitre Vascular in a research note on Friday, May 31st. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Finally, JMP Securities boosted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $90.33.

LeMaitre Vascular Trading Up 6.4 %

The firm has a market capitalization of $2.06 billion, a P/E ratio of 57.07, a P/E/G ratio of 2.63 and a beta of 0.89. The business’s fifty day moving average is $84.03 and its 200 day moving average is $74.17.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.37 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 29th. Investors of record on Thursday, August 15th will be paid a $0.16 dividend. The ex-dividend date is Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the completion of the sale, the chief executive officer now directly owns 1,985,358 shares of the company’s stock, valued at approximately $170,879,763.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,251 shares of company stock worth $3,714,994. Company insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co boosted its stake in shares of LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after buying an additional 6,875 shares during the period. Quantbot Technologies LP grew its stake in LeMaitre Vascular by 1,001.4% in the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after purchasing an additional 6,669 shares in the last quarter. Ranger Investment Management L.P. increased its position in LeMaitre Vascular by 1.5% in the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after purchasing an additional 13,681 shares during the last quarter. Congress Asset Management Co. MA increased its position in LeMaitre Vascular by 12.0% in the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after purchasing an additional 71,411 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of LeMaitre Vascular by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.